Howmet Aerospace Inc vs Revvity Inc — how do they compare? Howmet Aerospace Inc trades at $225.24 (market cap $88.76B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Howmet Aerospace Inc is far larger — about 5.2× Revvity Inc's market cap, and Howmet Aerospace Inc pays the higher dividend (0.25%). Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Revvity Inc for 12 Days on average.
| HWM | RVTY | |
|---|---|---|
Market Cap | $88.76B | $16.98B |
Volume | 2,648,516 | 1,456,900 |
Sector | Industrials | Health |
52-Week High | $292.65 | $157.36 |
52-Week Low | $184.09 | $82.26 |
Typical Hold Time | 35 Days | 12 Days |
Enterprise Value | $92.86B | $19.30B |
Dividend Yield | 0.25% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $225.24, up 1.14% with strong fundamental performance including three consecutive quarterly earnings beats. The stock shows bearish technical signals despite robust profitability metrics with 20.52% net income margin and 34.89% ROE. Recent news highlights defense aerospace strength and upcoming Q3 2026 earnings announcement on October 29, 2026.
Analyst consensus remains strongly bullish with 84% buy ratings and $328.10 price target representing 46% upside potential. Key risks include technical weakness, valuation multiples above industry averages, and dependence on aerospace sector recovery. The combination of strong fundamentals and analyst optimism suggests potential for recovery from current technical pressure.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →